| Hazard Information | Back Directory | [Description]
Blonanserin is a dopamine-D2 and serotonin-S2 antagonist. | [Uses]
Blonanserin dihydrochloride is a potent and orally active 5-HT2A and dopamine D2 receptor antagonist, with Ki values of 0.812 and 0.142 nM, respectively. Blonanserin dihydrochloride is usually acts as an atypical antipsychotic agent, and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension[1][2]. | [in vivo]
Blonanserin dihydrochloride (Oral gavage; 1 mg/kg; once a day for 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but preatment with blonanserin does not affect the social behaviors in saline-administered mice[2]. | Animal Model: | Mice received saline or phencyclidine once a day for 14 consecutive days[2] | | Dosage: | 1 mg/kg | | Administration: | Oral gavage; once a day for 14 days | | Result: | Had an effect on the social deficit in mice that received repeated PCP administration. |
| [IC 50]
D2 Receptor: 0.142 nM (Ki); D3 Receptor: 0.494 nM (Ki); D4 Receptor: 150 nM (Ki); D1 Receptor: 1070 nM (Ki); 5-HT2A Receptor: 0.812 nM (Ki); 5-HT2C Receptor: 26.4 nM (Ki); 5-HT6 Receptor: 11.7 nM (Ki); α1-adrenergic receptor: 26.7 nM (Ki); α2-adrenergic receptor: 530 nM (Ki) | [References]
[1] Blonanserin
[2] Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D 3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. Neurochem Int. 2019 Sep;128:127-134. DOI:10.1016/j.neuint.2019.04.008 |
|
|